Australian vaccine preventable disease epidemiological review series: mumps 2008-2012.

In 2007, Australia recorded the highest notification rate (2.8 per 100,000) for mumps since it became notifiable, with outbreaks in Western Australia and the Northern Territory. Of particular concern was the number of cases seen in vaccinated individuals. The aim of this study was to review subsequent epidemiological data. Notification, hospitalisation and mortality data from the National Notifiable Diseases Surveillance System, the National Hospital Morbidity Database and Australian Bureau of Statistics (ABS) respectively, from 2008 to 2012 for notifications and 2008 to 2011 for hospitalisations and deaths, were analysed by age, year and jurisdiction. ABS population data were used to calculate rates. National mumps notification rates decreased from 1.3 per 100,000 in 2008 to 0.4 per 100,000 in 2010, but then increased to 0.9 per 100,000 in 2012, predominantly due to increased notifications in New South Wales (1.4 per 100,000). Hospitalisation rates remained stable at 0.4 per 100,000 over the 2008-2011 period. The median age of notified cases was 30 years and for hospitalisations, 27 years. The highest rate of notifications and hospitalisations was in the 25-34 years age group. Completeness of vaccination status ranged from 16% to 39%. The increasing trend in mumps notifications needs to be closely monitored. Improved data quality, in particular on vaccination status, is needed to inform the monitoring of vaccine effectiveness. In March 2014 the World Health Organization certified that Australia had achieved measles elimination. Greater availability of case history (vaccination status and place of acquisition) and genotyping data would facilitate an assessment of Australia's progress in relation to mumps elimination.

Mumps: burden of disease in France.

This article provides a review of the epidemiological data on mumps in France since 1986. The results of 26 years of monitoring in general practice by the Sentinel network are analysed, such as hospitalisation data between 2004 and 2010, as well as mortality data between 2000 and 2009. The annual incidence rate has plummeted between 1986 and 2011, from 859 cases per 100,000 inhabitants [95% CI: 798-920] to 9 cases per 100,000 inhabitants [95% CI: 4-14]. A change in the age distribution is significant with an increase of Relative Illness Ratio (RIR) for patients over 20 years. Since 2000, vaccine status has also changed, and the majority of recent mumps cases occur among previously vaccinated patients. The average annual hospitalisation rate is 3.2 per 1 million inhabitants. Mumps was identified as the initial cause of death in 1 case every 5 years. This study estimates the burden of mumps disease in France.

[Analysis epidemiological and pathogen characters of mumps in China from 2004 to 2006].

OBJECTIVE: The study was conducted to analyze the epidemiological characteristics of mumps in China (Hong Kong, Macau and Taiwan excluded) from 2004 to 2006 and to provide basic data for mumps control. METHODS: Descriptive epidemiological analysis was conducted based on the data of epidemic parotitis from National Notifiable Disease Reporting System and mumps virus surveillance database from Nation Measles Lab. RESULTS: The annual incidence rates of parotitis cases during 2004-2006 were 17.45/100, 000, 22.40 /100, 000, 20.76 /100, 000 respectively. All the provinces had parotitis cases report. In all parotitis cases during 2004-2006, the percentage of case number of children (< 15 years old) were 89.77%, 87.87%, 85.15% respectively, while the children between 5-9 years old were 49. 16%, 46.90%, 43.26% respectively. The homology based on 316 nucleotides of the Chinese mumps virus isolated during 2004 - 2006 was 95.4%-100%. CONCLUSION: To prevent and control mumps, the mumps surveillance for serology, virology and eoidemiology should be strengthened in China.

Why we need to continue to immunize against mumps.

Since the introduction of the mumps vaccine in the U.S.A., the number of cases and those of associated complications of mumps have decreased, but the rates of complications have remained unchanged. The average age of those falling ill to mumps has increased because of the high degree of immunity among younger, immunized children. Rates of severe complications (encephalitis, death) are higher when the illness takes place at any age beyond the first decade of life, but increase particularly sharply in adulthood. Though an upward shift in age of those getting mumps has not yet been recorded in Switzerland, the relatively high rate of immunization among young children and a large group of susceptible older individuals means that similar conditions to those in the U.S. are present. We should continue to immunize susceptibles with the most effective available mumps vaccine because of this anticipated shift and the higher rates complications in older patients. The cost-benefit ratio of immunization compared to illness also speaks favorably for immunization.

Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants.

Until January 1989, mumps vaccine was not routinely administered in Israel, and rubella immunization was restricted to adolescent girls. The theoretical effect of combined mumps-rubella vaccination was applied to a population consisting of a cohort of 1-year-old children followed for 13 years. Assuming 90% compliance and 95% vaccine efficacy, projected clinical cases of mumps, rubella, encephalitis and thrombocytopenia would be reduced by 4,144; 3,109; 13; and 1 respectively. We anticipate a benefit to cost ratio of between 1.17 and 1.77 for the program. Since only 10-20% of cases are reported, the true benefit to cost ratio is likely to be at least 5.85. The benefit to cost ratio based on health service benefits alone is between 0.34 and 0.52; however, after adjusting for under-reporting, benefits are expected to exceed costs. Expenditures for laboratory testing, a factor not previously considered in such an analysis, would be reduced by approximately $2,750 per year. These results justify the initiation in January 1989 of nationwide routine vaccination.

Mumps surveillance in England and Wales 1962-81.

A study of routine data on mumps in England and Wales suggests that its epidemiological features are changing from those of an epidemic disease in young adults and older children to a more endemic disease in younger children. Infection now occurs at an earlier age, at which complications are less frequent and symptomless infection may be more common. The incidence of clinical disease may be falling. The high proportion of registered deaths in the middle aged and elderly may be an artifact due to misclassification of causes of death and to misdiagnosis. These changes lessen the need for routine immunisation. Indeed with low acceptance rates of measles vaccination of 50% at age 15 months, mumps/measles routine vaccination at the same age is contraindicated because similarly low acceptance rates might lead to an increase in the number of cases of mumps in older children and young adults, at which ages complications are more frequent.

Current status of mumps and mumps vaccine in the United States.

Reported mumps in the United States has declined to all-time low levels following the increasingly widespread use of mumps-virus vaccine. Mumps vaccine has proven safe and effective. Its incorporation into combined live-virus vaccines, especially measles-mumps-rubella, has made mumps vaccination a practical and economically feasible component of routine immunization activities. Because of the favorable experience to date with mumps vaccine and the associated drop in mumps morbidity and mortality, mumps control programs likely will receive increasing public health attention in the coming years.

A retrospective survey of the complications of mumps.

A retrospective survey is described of 2,482 cases of mumps (1,513 males and 969 females) treated in a number of infectious disease units in England and Wales. About half the patients were under 15 years of age. Complications were recorded in 42 per cent of all cases (53 per cent of males and 25 per cent of females), the commonest complication in both sexes being involvement of the central nervous system. Three patients died, but in two of these there was serious underlying illness unrelated to mumps and in the remaining case a review of the records suggests, in retrospect, some doubt about the diagnosis of mumps. Deafness due to involvement of the eighth cranial nerve was the only permanent sequel recorded and occurred in five patients.From the results of this survey it is concluded that there is little need for general vaccination against mumps, although there might be an indication for vaccinating certain groups of the male population.